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(1) Clinical trials of immune checkpoint inhibitors (ICPIs) have ascribed HCC to the expanding list of tumors characterized by intrinsic sensitivity to immunotherapy. In particular, these agents have been proven effective in advanced melanoma, renal cell carcinoma, and non-small-cell lung cancer (NSCLC), with an increasing number of studies demonstrating response rates of up to 25% across hematological and solid malignancies. However, despite the unprecedented efficacy of ICPIs, patients with HCC represent a population with distinct features. The concomitant presence of cirrhosis in >80% of patients is unique and deserves to be considered for its potential safety impact on the delivery of immunotherapy.
In terms of efficacy, the presence of a predominantly immunosuppressive microenvironment within
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the liver might affect long-term disease control in patients with HCC. Attempts to personalize development of ICPIs through multitechnology profiling of tumor samples poses a conflict with routine clinical practice, in which histological confirmation of the diagnosis has been largely abandoned in favor of radiologic criteria. (2) In the context of a rapid expansion of immunooncology, this review aims to outline the challenges and opportunities that accompany the clinical development of immunotherapy in HCC. Here, we review the basic immunobiological foundations justifying the disease-modulating role of immunotherapy in HCC and attempt to define how ICPIs may be positioned alongside the evolving landscape of radical, locoregional, and systemic treatments for HCC.
Rationale for Development of ICPI in HCC tHe lIVeR aS aN IMMUNologICal gateKeepeR
The liver sits at the junction between the host and a continuous influx of gut nutrients, toxins, and metabolites from its evolving microbiome. The plethora of immunological interactions within the gut-liver axis plays a significant role in health and disease and participates in the pathogenesis and progression of HCC. Among the physiological functions of the liver in governing host defense, the process of immune distinction between gut pathogens and self requires polarization of intrahepatic immune cells toward immunosuppression. However, in chronic liver inflammation induced by various hepatotropic noxae, enhancement of gut permeability ("leaky gut") may further polarize the liver microenvironment toward immunosuppression. (3) Dissection of this complex interplay has highlighted a predominant role of intestinal dysbiosis in facilitating fibrogenesis through hepatic stellate cell (HSC) activation. (4) The resulting immunosuppressive milieu typical of progressive chronic liver diseases profoundly modulates HCC growth by facilitating immune evasion. (5) tHe IMMUNe laNDSCape oF HCC Impaired antigen presentation through alterations in major histocompatibility complex (MHC) class I and aberrant expression of tumor neoantigens (6) are key mechanisms facilitating immune escape in HCC. Effector T-cell function impairment occurs both by reduced recruitment of CD4 + and cytotoxic CD8 + (cytotoxic T lymphocytes; CTLs) tumor-infiltrating lymphocytes (TILs) as well as activation and expansion of tolerogenic dendritic cells (DCs) and regulatory T cells (T-regs). (7) Other cell types involved in immune evasion include myeloid-derived suppressor cells (MDSCs), (7) HSCs, and tumor-associated macrophages (TAMs). MDSCs are functionally heterogeneous cells possessing T-cell-suppressive activity in cirrhosis and HCC. Immunosuppressive M2-polarized TAMs promote HCC growth and invasion predominantly by CCL22 chemokine secretion. (8) Concurrently, HSC activation drives an inflamed, profibrogenic microenvironment, with enrichment of HSC-specific transcripts predicting outcome after HCC resection. (9) Acknowledging the functional heterogeneity of the tumor microenvironment (TME) of
HCC is a point of greater consequence in the development of strategies to overcome immunotherapy resistance.
HaRNeSSINg tHe IMMUNogeNICIty oF HCC
Despite the predominantly immunosuppressive microenvironment, certain patients can mount protective immunity to HCC with anecdotal evidence of spontaneous remission. (10) Altered neoepitope expression is common in HCC, (6) in which chronically inflamed hepatocytes express a repertoire of tumor-associated antigens (TAAs), including alpha-fetoprotein (AFP), glypican-3, and many other cancer/testis antigens. (11) Dense TIL infiltration and high prevalence of TAA-specific T-cell peripheral responses are commonly found (12) ; however, T-cell responses against immune-dominant epitopes exist in a suppressed state in HCC patients. (13) The presence of an immune-reactive microenvironment in HCC, rich in potentially actionable drivers of the immune response, has been evident since the earliest genomic studies of HCC. In a study of 956 HCC patients, 25% clustered within a coordinated proinflammatory gene expression profile, with increased programmed death 1 (PD-1)/programmed death-ligand 1 (PD-L1) expression, fewer chromosomal aberrations, and dampened cytolytic activity. (14) Interestingly, proinflammatory gene-expression signatures clustered with dysregulation of transforming growth factor beta (TGF-β) signaling, consistent with enrichment of an exhausted immune response, suggesting this molecular subclass to be potentially sensitive to ICPIs. Figure 1 summarizes some of the key therapeutically-relevant interactions within the HCC TME.
Classes of the Forerunner Checkpoint Molecules and Their Inhibitors
CytotoXIC t-lyMpHoCyteaSSoCIateD aNtIgeN 4
Although cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) expression is not prognostic in HCC, (15) the ubiquity of CTLA-4 on T-regs and activated CTLs suggests its clinical value as a therapeutic target. Disruption of CTLA-4/CD80-CD86 interaction results in tumor rejection through enhancement of T-cell effector responses and is associated with selective T-reg depletion. (16) Ipilimumab and tremelimumab are monoclonal antibodies (mAbs) against CTLA-4 that have both been studied in HCC (Table 1 ). In a small phase II trial of 21 patients with hepatitis C virus (HCV)-associated HCC, tremelimumab demonstrated antitumor and antiviral activity defined by an overall response rate (ORR) of 17.6%, a median time to progression (TTP) of 6.5 months, and reduction in HCV viremia in a subgroup of patients. (17) Interestingly, tremelimumab enhances CTL density in HCC, providing justification for its combination with locoregional therapies (LRTs). (18) Although concern exists over the greater toxicity of CTLA-4 inhibitors compared to anti-PD-1 therapies, an increasingly relevant role for these molecules stems from their use in combination. In HCC, ipilimumab and tremelimumab are being tested in combination with nivolumab (NCT01658878) and durvalumab (NCT02519348), respectively.
pD-1 aND ItS lIgaNDS (pD-l1/pD-l2)
Binding of either PD-L1 or PD-L2 to PD-1 on T cells inhibits their activation. PD-L1 is highly expressed in HCC and surrounding antigenpresenting cells (APCs) with prevalence ranging from 45% to 100%. (19) PD-L1 expression appears stage independent and influences overall survival (OS), disease-free survival, grade, and vascular invasion in early-stage HCC. (19) Pembrolizumab and nivolumab are potent and highly selective PD-1-targeting mAbs, whereas atezolizumab, avelumab, and durvalumab target PD-L1. Nivolumab was licensed by the United States Food and Drug Administration (FDA) for advanced HCC on the basis of Checkmate-040, a phase I study of sorafenib-intolerant or -refractory patients, stratified by hepatitis B/C etiology. (20) Eligibility was restricted to patients with good performance status (0-1), Child-Pugh score ≤7 for dose-escalation, and ≤6 for dose expansion and evidence of adequate hepatitis B virus (HBV ) control on antivirals. At 3 mg/kg every 2 weeks, nivolumab resulted in 25% of patients developing treatment-related grade 3 or 4 toxicities, of which 6% were reported as serious adverse effects (AEs) affecting skin, adrenal glands, and liver. Encouragingly, an ORR of 20% and a promising 1-year OS rate of 62% were demonstrated. Similarly, preliminary results of second-line treatment with pembrolizumab following sorafenib failure have demonstrated an ORR of 16.3% and a 6-month OS rate of 77.9%. + T-cell activation. Abbreviations: CCR4, C-C chemokine receptor type 4; DAMPs, damage-associated molecular patterns; HIF-1α, hypoxia-inducible factor-1 alpha; PAMPs, pathogen-associated molecular patterns; RFA, radiofrequency ablation; TACE, transarterial chemoembolization; VEGF, vascular endothelial growth factor. landscape. Although codified prognostic algorithms, such as the Barcelona Clinic Liver Cancer (BCLC) staging system, have guided treatment allocation in routine care since the early 2000s, the rapid clinical development of ICPIs is expected to significantly change this framework.
early-Stage Disease: Can ICpIs Improve Cure Rates in HCC?
Although curative of both cancer and cirrhosis, orthotopic liver transplantation (OLT) is restricted to patients who satisfy stringent criteria. (22) Despite high cure rates, the issue of post-transplant recurrence, common in 10% of patients fulfilling Milan criteria (23) and in many more patients outside these, (24) suggests that OLT is inadequate as a single therapeutic modality in guaranteeing lifetime disease control in a proportion of patients. Tumor recurrence is even greater following liver resection, with relapse rates up to 70% with 5-year OS figures ranging between 17 and 53%. (25) Antitumor immunity is mechanistically involved in modulating the risk of HCC relapse, (26) highlighting the rationale for the development of ICPIs alongside curative treatments for HCC.
perspectives for Neoadjuvant Use of ICpIs
Neoadjuvant ICPI therapy offers the advantage of assessing sensitivity to treatment in the individual patient: Achievement of a pathological complete response (pCR) is one of the strongest predictors of long-term survival, with paradigmatic examples across a number of malignancies. Such a prognostic role holds true in HCC, in which response to bridging therapy in OLT candidates predicts for improved prognosis. (27) Neoadjuvant therapy has traditionally been a challenge in HCC, particularly because of the lack of systemic agents capable of inducing significant Abbreviations: ALT, alanine aminotransferase; HBV hepatitis B virus; HCV hepatitis C virus; ITT, intention to treat; ORR, overall response rates.
downstaging of the disease. Although transarterial chemoembolization (TACE) and yttrium-90 radioembolization have been attempted in the pre-OLT setting to reduce drop-out rates and maximize transplant eligibility, evidence of a survival benefit is exclusively based on retrospective data. (28) Considering the treatment landscape of HCC, patients who are candidates for liver resection and not eligible for OLT represent the most suitable population to preliminarily investigate the neoadjuvant use of ICPIs, aiming to positively impact on surgical outcomes and control relapse risk.
Combination ICPI therapy with ipilimumab (3 mg/kg) and nivolumab (1 mg/kg) is being tested in the two-arm phase Ib OpACIN (Optimal Adjuvant Combination Scheme of Ipilimumab and Nivolumab in Melanoma Patients) trial in melanoma as an adjuvant (four courses postsurgery; n = 10) or neoadjuvant therapy (split into two courses presurgery and two postsurgery; n = 10). Although no additive perioperative morbidity has been observed, discontinuation rates attributed to toxicity appear to be particularly high in this study (90%), in which only 2 patients were able to complete the predefined treatment schedule. Despite high toxicity, a radiological complete response was observed in 80% of patients treated neoadjuvantly with an encouraging 30% pCR rate. (29) In the setting of liver resection for HCC, the selected delivery of ICPI to patients who have adequate liver functional and physical reserve to cope with anticipated immunotoxicity mitigates the potential safety concerns linked with the delivery of systemic therapy. However, a number of issues in the delivery of the neoadjuvant treatment schedule remain unanswered, including patient selection, optimal duration of treatment, and choice of single-agent versus combined ICPI approach. The appealing ORR and median OS (mOS) achieved by combined CTLA-4/PD-1 inhibition in other indications, in excess of 30%-40%, are appealing but discouraged by the high proportion of grade 3-4 AEs, which can exceed 50%. (30) Given that safety and efficacy data from dual checkpoint inhibition will prospectively emerge in advanced HCC, appropriate dose-adapted schedules should be evaluated, with a focus on immune-mediated hepatotoxicity, which, although common in 5%-10% of patients treated with single-agent anti-PD-1 inhibitors, tends to be significantly higher with combined therapy. (30) Despite the optimistic prospects, the complexity of HCC requires caution in the development of ICPIs in transplant candidates. Based on historical data, ideal candidates for neoadjuvant ICPIs are patients at higher risk of post-OLT relapse, specifically those with multifocal tumors, higher AFP levels, higher tumor volume, and poorer differentiation. (31) However, the need for lifetime immunosuppression in patients with OLT might represent a barrier to the safe delivery of ICPI therapy, attributed to its documented potential of precipitating graft rejection. (32) Most trials of ICPIs exclude patients on long-term immunosuppression, such as transplant recipients, therefore evidence to support their safe use is limited in this population. In a pilot study, ICPI-mediated allograft rejection was documented in 1 of 6 treated patients, (33) underscoring the need for larger studies to inform safe integration of ICPI therapy in transplant recipients.
adjuvant ICpI therapy
Although sorafenib after liver resection/radiofrequency ablation (RFA) has failed to demonstrate a significant relapse-free survival/OS benefit, (34) multiple studies have highlighted adequate control of etiological factors, such as HBV suppression (35) or HCV eradication, (36) as key determinants of long-term survival in early-stage HCC. These studies emphasize the role of the TME in shaping the risk of relapse, a contribution that may potentially confound the assessment of benefit from tumor-directed adjuvant interventions. Cytokine-induced killer (CIK) cell therapy, defined by the infusion of autologous peripheral blood mononuclear cells after treatment with interleukin (IL)-2, may reduce relapses and increase survival according to randomized trials. (37) However, the precise immunobiological mechanisms underlying efficacy are poorly understood, and the need for specialist expertise to deliver CIK has limited the use of this approach.
A key challenge in the optimal delivery of adjuvant ICPI therapy in HCC stems from the multifactorial nature of HCC relapse. Early intrahepatic recurrence is traditionally attributed to true disease reoccurrence after radical treatment as opposed to de novo tumor formation, with a 2-year cut-off period suggested as an empirical threshold to differentiate the two entities. (38) Although adjuvant ICPI is expected to reduce recurrence by facilitating systemic clearance of residual micrometastatic disease and prolonging progression-free survival, the potential for a "chemopreventative" role of immunotherapy in influencing de novo tumorigenesis is based on much-less-solid evidence. Identification of histopathological high-risk features postresection, including higher tumor burden, poorer differentiation, multifocality, and most importantly, microvascular invasion may aid the identification of optimal candidates for adjuvant treatment.
Perhaps more strongly than in the neoadjuvant setting, adjuvant ICPI therapy in HCC lacks clear guidance in terms of duration of therapy and choice of agents. Toxicity, which was significant in the adjuvant melanoma study, EORTC (European Organisation for Research and Treatment of Cancer) 18071, (39) might limit the selection of a CTLA-4 inhibitor in the adjuvant setting in HCC.
INtegRatINg ICpI WItH lRts
Despite active screening programs, approximately 50%-60% of HCC cases present with intermediate-stage disease in which TACE is the recommended first-line therapy. (40) Wide clinical heterogeneity exists in this patient population who will inevitably progress after TACE with a mOS of 24 months. (41) Migration of this patient group to systemic treatment is possible, but survival outcomes are poor because of the limited efficacy of sorafenib. (42) Combination of TACE with antiangiogenic therapies has failed to improve outcomes. (43) Adaptive T-cell responses against TAAs are key mechanisms regulating tumor rejection in HCC. These can be enhanced in vivo using autologous DC vaccines or by tumor lysate stimulation (44) and are dynamically modulated in response to TACE. (13) Similarly, regulation of T-cell-suppressive responses relates to the efficacy of TACE and makes restoration of effective antitumor adaptive immunity an appealing therapeutic strategy in HCC. A key question is whether the ischemic damage imposed by TACE may facilitate priming to a broad range of previously inaccessible neoepitopes and exert synergistic antitumor effects with immunotherapy. TACE plays a role in activating a hypoxic response, promoting the release of vascular endothelial growth factor (VEGF) and other proangiogenic cytokines. (45) Evidence suggests that PD-L1 expression is transcriptionally regulated by hypoxia-inducible factor (HIF-1α), (46) which strengthens the rationale of combining TACE with PD-1/PD-L1 inhibitors. Figure 2 summarizes the key immune-modulating effects of RFA and TACE.
In a pilot study of tremelimumab following subtotal chemoembolization or RFA in 32 patients with HCC, an ORR was observed in 5 of 19 evaluable patients (26%) with TTP of 7.4 months. (18) Posttreatment tumor biopsies showed enhanced CTL infiltration, qualifying TACE as an immunogenic cell death (ICD) inducer. Although encouraging, the small sample size and lack of comparator arms in this trial do not allow dissection of the individual role of tremelimumab as a synergistically acting agent in promoting ICD. A number of studies are ongoing in this area, including PETAL (PEmbrolizumab and TACE in primary Liver carcinoma), the first trial to explore the safety, tolerability, and preliminary bioactivity of pembrolizumab in combination with TACE in intermediate-stage HCC (NCT03397654), and a second study evaluating nivolumab in association with drug-eluting bead/TACE (NCT03143270). The results of these studies will be instrumental in planning proof-of-concept, multicenter phase II/III studies.
aDVaNCeD DISeaSe: eVolVINg RatIoNale FoR IMMUNotHeRapy CoMBINatIoNS
In contrast to other cancer types, systemic treatments have traditionally played a comparatively modest role in advanced HCC, in which mOS rarely extends beyond 1 year. Among a number of latestage failures in clinical development, the provision of systemic anticancer treatment in HCC is still unsupported by predictive correlates of response, (47) a point of greater consequence now that treatment options for HCC are expanding from sorafenib to alternative first-line options with lenvatinib and second-line therapies with regorafenib and cabozantinib. (48) With immunotherapy displaying evidence of disease-modulating effects in HCC as a single agent, the rationale for combination strategies is becoming evident. Table 2 provides a summary of openly recruiting combination trials in the advanced disease setting.
FIg. 2.
Immune-modulating effects of LRTs for HCC. RFA induces vascular disruption and vasoconstriction, causing necrosis of tumor cells and release of both damage-associated molecular patterns (DAMPs) and pathogen-associated molecular patterns (PAMPs). These induce changes in the immunological milieu, including an increase in CD4 + and cytotoxic CD8 + T cells, but reduce T-reg cell infiltration. TACE is delivered by vessel catheterization inducing ischemia, which drives both necrosis and apoptosis of tumor cells. Similarly, the release of DAMPs and PAMPs drives changes in the tumor microenvironment, which include the increased infiltration of CD4 + and cytotoxic CD8 + T cells, as well as the increased release of growth factors, HIF-1α and VEGF. CD4 + T cells present released antigens to APCs, which, stimulated by cytokines, including IL-12, IL-14, and type 1 IFN-γ, activate NK cells and CD8 + T cells. Abbreviations: CCR4, C-C chemokine receptor type 4; FasL, Fas ligand; GPC-3, glypican-3; IFNGR1, interferon gamma receptor 1; IFNGR2, interferon gamma receptor 2; LGALS-1, lectin, galactoside-binding, soluble 1; MAGE-A1, melanoma antigen gene encoding-A1; NY-ESO-1, New York esophageal squamous cell carcinoma 1; TCR, T-cell receptor.
Combination Immuno-oncological approaches
Combination of PD-1 and CTLA-4 receptor blockade has proven synergistic in preclinical and clinical studies in melanoma, in which an ORR of 57% was demonstrated. (30) ORRs of 38%-47% and 42% have since been respectively reported in the first-line treatment of NSCLC and renal cell carcinoma. (49, 50) The expanding ICPI efficacy data across solid tumor indications are encouraging, but toxicity concerns have driven research toward defining the relative contribution of PD-1/ PD-L1 versus CTLA-4 blockade in determining depth and durability of responses. Preliminary data from the durvalumab/tremelimumab phase I HCC study suggest that this combination is well tolerated, with the most frequent treatment-related AEs being asymptomatic aspartate aminotransferase (AST) rise (10%). Efficacy seems encouraging, with an ORR of 35% demonstrated in patients who were not virally infected. (51) Similarly to other indications, there is a rationale to block other immune checkpoints (lymphocyte-activation gene 3, T-cell immunoglobulin and mucin-domain containing-3) and to evaluate antibodies that agonistically bind costimulatory receptors on immune cells (OX40, glucocorticoid-induced tumor necrosis factor receptor, and CD137) to enhance the efficacy of ICPI. (52) Therapeutic modulation of some of these targets is hypothesized to synergize with PD-1 by their alternative mechanism of action with lower anticipated toxicity than CTLA-4 inhibitors. The combination of nivolumab and the anti-CCR4 antibody, mogamulizumab, which has shown efficacy in T-cell lymphomas, (53) is being tested in an open phase I/II trial in HCC (NCT02705105). Targeting the cytokine drive toward immunosuppression may be especially relevant in view of the inflammatory nature of HCC, and the combination of the TGF-β inhibitor, galunisertib, with nivolumab in patients with refractory HCC (NCT02423343) is under investigation. Natural killer (NK) cells mediate antitumor activity both by innate immune and antibody-dependent cell-mediated cytotoxicity (ADCC). Therapeutic modulation of NK function with the anti-KIR (killer inhibitor receptor) antibody, lirilumab, is under investigation in combination with nivolumab (NCT01714739). An alternative approach is targeting TME metabolism inhibition of the immunosuppressive enzyme, indoleamine-2,3 dioxygenase (IDO), a strategy tested by combining epacadostat, an IDO-inhibitor, with pembrolizumab in solid tumours, including in HCC (NCT02178722). Other combination approaches include epigenetic enhancement of antitumor immunity through histone deacetylation inhibition, which is supported by preclinical evidence suggesting increased HCC cell line apoptosis with vorinostat. (54) antiangiogenics and other tyrosine Kinase Inhibitors
Emerging evidence suggests that antiangiogenic therapies may also have immunomodulatory effects. Tyrosine kinase inhibitors can exert "off-target" effects on the TME, including vascular stabilization and changes in tumour perfusion; and may exert a conditioning role on TILs, that suggest the Abbreviations: AXL, AXL receptor tyrosine kinase; c-MET, hepatocyte growth factor receptor; CCR4, C-C chemokine receptor type 4; KIR, natural killer cell inhibitor receptor; PDGFR, platelet-derived growth factor receptor; VEGFR, vascular endothelial growth factor receptor.
potential for synergy with ICPIs. (55) Sorafenib has been shown to modulate infiltration of inflammatory cells, including CTLs (56) and NK cells. (57) Combination treatment with sorafenib and inhibitors of stromal-derived-factor-1a receptor have shown incremental antitumor efficacy maximized by the concomitant inhibition of PD-L1. (58) Clinically, potential synergistic combinations between antiangiogenics and ICPIs are being explored in advanced HCC. The first-line combination of sorafenib with nivolumab is being tested in a phase II trial (NCT03439891), whereas the expansion of the Checkmate 040 study now has alternative VEGF receptor (VEGFR) inhibitor arms, including combination with sorafenib and cabozantanib (NCT01658878). Other combination trials of axitinib with avelumab (NCT03289533) and of the METinhibitor, capmatanib, with the anti-PD-1 inhibitor, PDR-001, are currently recruiting (NCT02795429).
Cellular Immunotherapy
Although the use of vaccines with (59) or without DC infusions (60) has thus far been disappointing in the clinic, evidence of antitumor effects, including on circulating cytokine and AFP levels within these trials, warrants further research on cellular immunotherapy perhaps in combination with ICPIs. Intratumoral injections of oncolytic and immunotherapeutic vaccinia virus JX-594 (pexa-vec) have shown an early signal of antitumor efficacy (61) and have provided the rationale for an ongoing first-line phase III study comparing the combination of JX-594 with sorafenib versus sorafenib alone (NCT02562755) and in combination with nivolumab (NCT03071094).
pReDICtINg eFFICaCy to ICpI: tHe CHalleNge oF patIeNt SeleCtIoN
Although ICPIs represent a novel and effective therapeutic class in the oncology clinic, response rates to single-agent immunotherapy is limited to 20% of patients across indications. As newer therapies expand in the treatment of advanced HCC, identification of predictive correlates of response is becoming critical to spare patients from potentially life-threatening toxicity in the absence of clinical benefit. PD-L1 expression by immunohistochemistry (IHC) has been suggested to underscore responsiveness to ICPIs in selected tumour types. However, such a role has not been replicated in HCC. Heterogeneity in PD-L1 IHC assays exists and may have clinical implications in disease stratification. Efficacy of ICPI relies on the breadth and depth of effector T-cell responses. Enrichment of interferon-gamma (IFN-γ)-related signatures identified through transcriptomic profiling is a common trait of ICPI-responsive malignancies. (62) Microsatellite instability occurs because of defective mismatch repair (MMR) and leads to a somatic hypermutated phenotype with higher neoantigen burden. The exquisite immunogenicity of microsatellite-unstable malignancies was demonstrated by the high response rates to anti-PD-1 therapies across histotypes, (63) leading to the first tumor agnostic FDA approval of pembrolizumab in MMR-deficient solid tumors irrespective of histology. Higher tumor mutational burden (TMB) induces a polyclonal, efficacious T-cell effector response by promoting a broadened recognition of tumor neoantigens. HCC typically demonstrates a moderate TMB, amounting to two mutations/megabase, further underscoring the overall antigenic potential of HCC. (64) The link between higher TMB and responsiveness to PD-1/PD-L1 blockade (65) is established in melanoma and NSCLC, suggesting a better predictive role than PD-L1 expression across tumor types. (66) Although linked to worse prognosis, (67) the predictive role of this biomarker, TMB, for ICPI efficacy in HCC should be prospectively tested. A number of other factors may modulate responsiveness to immunotherapy, including etiology of underlying liver disease, and TIL density and composition. (68) Interestingly, despite the wide heterogeneity characterizing the composition and functionality of the liver-resident immune infiltrate across the various etiologies of HCC, patients with non-HCV-/ non-HBV-mediated HCC had similar responses to virally induced HCC in both Keynote-224 (21) and Checkmate-040, (20) suggesting independence between antitumor activity and viral etiology of HCC. A number of other host determinants are known to reduce effector T-cell activity. Given the strong pathogenic link between gut dysbiosis and the molecular pathogenesis of HCC in cirrhosis, studies evaluating the role of bacterial phylogeny with the characteristics of the antitumor immune response should be prioritized. Other host factors include the presence of a systemic inflammatory response, (69) circulating cytokine levels, and changes in immune effector composition, which deserve evaluation for a predictive role in HCC. (68) 
Conclusion
After a decade of stagnation in drug development, therapeutic reversal of immune-exhaustion with PD-1-targeting ICPIs has been shown to improve survival outcomes. Rampant clinical development of novel ICPIs, either as monotherapy or in combination, has rapidly followed in an attempt to improve on the 20% ORR observed in early-phase trials of PD-1-targeted therapies. Despite widespread optimism, the development program of ICPIs in HCC should be interpreted cautiously. In HCC alone, as of the end of March 2018, there were at least 57 openly recruiting trials of immunotherapeutic agents registered on clinicaltrials.gov. (70) Although seamless clinical development of immunotherapies has certainly helped patients to obtain expedited access to novel therapies, the parallel testing of multiple therapeutic combinations in small proof-of-concept studies has been questioned for its efficiency.
As highlighted in this review, the specific context of HCC is accompanied by various factors that further complicate the drug-development process. Concerns over safety and tolerability of ICPIs, patient selection based on clinical characteristics and stage rather than biomarkers, as well as the documented influence of treatment-related and geographical heterogeneity in patient survival are among the key disease-specific issues ascribing HCC patients as a challenging population. Anecdotal evidence showing complete responses from anti-PD-1 therapy in BCLC-D disease are highly provocative, but consistent with concurrent evidence questioning poor performance status and organ dysfunction as absolute contraindications for systemic anticancer treatment. (71) To overcome these numerous challenges, the successful development of ICPIs in HCC will require the concerted efforts of various stakeholders across industry, academic, and regulatory bodies.
